Journals / art / 2015 / Cilt: 30 - Sayı: 3

Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis

Journal
art
Pages
221–225
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

EFT is a noninvasive method to evaluate cardiometabolic risk factors in AS patients

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aims to evaluate cardiometabolic risk factors in ankylosing spondylitis (AS) patients and their relationship with epicardial fat thickness (EFT).
📊
Key Findings & Data:Patients and methods: The study included 50 consecutive AS patients (29 males, 21 females; mean age 40.5±9.4 years; range 25 to 60 years) with a median disease duration of 8.3 years and 50 healthy controls (33 males, 17 females; mean age 39.8±6.4 years, range 24 to 58 years).
💡
Conclusion & Impact:EFT is a noninvasive method to evaluate cardiometabolic risk factors in AS patients
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: This study aims to evaluate cardiometabolic risk factors in ankylosing spondylitis (AS) patients and their relationship with epicardial fat thickness (EFT). Patients and methods: The study included 50 consecutive AS patients (29 males, 21 females; mean age 40.5±9.4 years; range 25 to 60 years) with a median disease duration of 8.3 years and 50 healthy controls (33 males, 17 females; mean age 39.8±6.4 years, range 24 to 58 years). All patients’ EFT was measured with echocardiography. Results: Both body mass index and waist circumference measurements were higher in AS patients than healthy controls (25.4±3.5. vs. 24.5±2.9 kg/m2 , p=0.005; 96.2±10.8 vs. 86.7±12.6 cm, p<0.001; respectively). Triglyceride levels were higher in AS patients than healthy controls (123.0±47.7 vs. 110.1±61.0 mg/dL, p=0.009; respectively). High-density lipoprotein cholesterol levels were lower in AS patients than healthy controls (41.3±7.0 vs. 51.9±7.0 mg/dL, p<0.001; respectively). The EFT of AS patients was greater (0.53±0.14 vs. 0.45±0.02 cm, p<0.001; respectively) and was positively correlated with age (r=0.420, p=0.002), disease duration (r=0.609, p<0.001), body mass index (r=0.419, p=0.002), waist circumference (r=0.469, p<0.001), and triglyceride (r=0.434, p=0.002) levels; and negatively correlated with high-density lipoprotein cholesterol levels (r= -0.662, p<0.001). Conclusion: As a cardiometabolic risk factor, EFT was greater in AS patients. EFT is a noninvasive method to evaluate cardiometabolic risk factors in AS patients

🔖

Cite This Article

UÇAR, M., SARIKAYA, S., SARP, Ü., TURAN, Y., AKYOL, L., BÖREKCİ, E., ERBAY, A. R., DEMİR, V. (2015). Cardiometabolic Risk Factors in Patients With Ankylosing Spondylitis. art, Cilt: 30 - Sayı: 3, 221–225. https://ajindex.com/articles/351775

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Genre F, López-Mejías R, Rueda-Gotor J, MirandaFilloy JA, Ubilla B, Carnero-López B, et al. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-alpha therapy have higher TRAIL levels than controls: a potential compensatory effect. Mediators Inflamm 2014;2014:798060. 2. van der Horst-Bruinsma IE, Nurmohamed MT, Landewé RB. Comorbidities in patients with spondyloarthritis. Rheum Dis Clin North Am 2012;38:523-38
  2. Bremander A, Petersson IF, Bergman S, Englund M. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011;63:550-6
  3. Gonzalez-Juanatey C, Vazquez-Rodriguez TR, Miranda-Filloy JA, Dierssen T, Vaqueiro I, Blanco R, et al. The high prevalence of subclinical atherosclerosis in patients with ankylosing spondylitis without clinically evident cardiovascular disease. Medicine (Baltimore) 2009;88:358-65
  4. Mathieu S, Motreff P, Soubrier M. Spondyloarthropathies: an independent cardiovascular risk factor? Joint Bone Spine 2010;77:542-5
  5. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med 2005;2:536-43
  6. Iacobellis G, Ribaudo MC, Assael F, Vecci E, Tiberti C, Zappaterreno A, et al. Echocardiographic epicardial adipose tissue is related to anthropometric and clinical parameters of metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab 2003;88:5163-8
  7. Malavazos AE, Ermetici F, Cereda E, Coman C, Locati M, Morricone L, et al. Epicardial fat thickness: relationship with plasma visfatin and plasminogen activator inhibitor-1 levels in visceral obesity. Nutr Metab Cardiovasc Dis 2008;18:523-30
  8. Kremen J, Dolinkova M, Krajickova J, Blaha J, Anderlova K, Lacinova Z, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab 2006;91:4620-7
  9. Iacobellis G, Bianco AC. Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features. Trends Endocrinol Metab 2011;22:450-7
  10. Iacobellis G, Lonn E, Lamy A, Singh N, Sharma AM. Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol 2011;146:452-4
  11. Nilgun U, Kurt M, Atcı N, Ya¤ız E, Güler H, Turhano¤lu A. Increased Epicardial Fat Tissue is a